SEC Form 4 · accession 0001804567-26-000014
SUPERNUS PHARMACEUTICALS, INC. · SUPN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Frank Mottola
Officer — SVP, Chief Tech. Ops. Officer
Period of report
Aug 12, 2026
Accepted (ET)
Aug 14, 2026 · 5:10 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001356576
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Aug 12, 2026 | M | 1,650 | $0.00 | A | 20,341 | D | |
| Common StockF2 | Aug 12, 2026 | F | 797 | $46.57 | D | 19,544 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Performance Share UnitF3 | $0.00 | Aug 12, 2026 | M | 1,650 | D | — | — | Common Stock | 1,650 | 0 | D |
Explanation of responses
- F1Includes an aggregate of 251 shares acquired by the Reporting Person through the Issuer's Employee Stock Purchase Plan.
- F2Represents the number of shares of common stock withheld by the Company to satisfy tax withholding requirements in connection with the vesting of Performance Share Units.
- F3On February 19, 2025, the Reporting Person was awarded Performance Share Units, a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on May 3, 2025.